Safety of sumatriptan in pregnancy: a review of the data so far.

摘要: The high prevalence of migraine in women during their reproductive years means that new drug treatments for migraine, such as the serotonin 5-HT(1B/1D) receptor agonists (the 'triptans'), are likely to be widely used by childbearing potential. Scrutiny these agents an effort detect any signal teratogenicity is thus important. A systematic review medical literature was conducted identify information regarding safety sumatriptan pregnancy. This agent chosen investigated because it has been available longest and most triptan class. Information obtained impact on pregnancy outcome, data use were from animal studies, preclinical trials, postmarketing surveillance efforts, prospective registries, national birth registries teratogen services. Synthesis sources sufficient rule out a large increase defects reassuring cases where inadvertent exposure occurred. However, current not small increases risk defects. For this reason, caution should exercised making positive recommendation